KeyZell Start-Up Plans to Reach 5 million Euros in Private Investment and Become the new Biotech Unicorn
PR95041
MADRID, March 17, 2022 /PRNewswire=KYODO JBN/ --
KeyZell, a Spanish biotechnology company in the development phase of
digital cancer treatments and tools, has just opened a private financing round
which expects to achieve 5 million euros to boost its projects and consolidate
itself as one of the biotech start-ups with the greatest international
projection.
KeyZell launches this new round of private investment to conduct a human
clinical trial with one of its innovative cancer treatments, based on Dr. Nabil
Hajji's research on cellular apoptosis induced by cell receptor blockage, as
well as to improve its precision medicine Artificial Intelligence system that
aims to be the future of cancer medicine, thanks to an algorithm that proposes
the most appropriate personalized treatment for each patient depending on the
unique characteristics of each person and type of cancer.
KeyZell has already generated great interest from both national private
investors and North American investment funds and has successfully closed a
preliminary round of 450,000 euros, 50% above expectations. Among its investors
are professional brokers as well as Spanish and Mexican businessmen.
"We created KeyZell with the objective of developing new cancer solutions
and tools that can help both medical professionals and patients in their fight
against this disease. This financing round will allow us to achieve our
ambitious objective," says Jose del Corral, company CEO.
The company is committed to blockchain technology, implementing
improvements on its AI-based tool and thus reinforcing this through clinical
trials. Keyzell plans to finance the clinical trial in Australia while in
negotiations with a strategic partner to carry out another trial in Mexico. In
addition, working on the structures to carry out regulatory processes in
Europe, United States, United Kingdom, Thailand, South Africa, Morocco and
Canada.
Keyzell has the pleasure of having Dr. Nabil Hajji among its founders who
has led the research with collaborators from University of Seville and Harvard
University, where they have discovered a new treatment which for the first
time, after more than twenty years without advances in glioblastoma research,
has succeeded in eliminating the most aggressive brain cancer, glioblastoma.
Media Contact:
Inés Martínez
imartinez@tinkle.es
+34 661 750 597
Source: KeyZell
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。